2023 World Conference on Lung Cancer (Posters)-P2.14. Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study

Pdf Summary

The analysis explores the use of atezolizumab (ATZ) beyond disease progression in patients with untreated extensive-stage small cell lung cancer (ES-SCLC). It focuses on the impact of ATZ-TBP on patient outcomes. <br />The study includes 118 patients with progressive disease who were divided into three groups: ATZ-TBP (26.9%), Other-Tx (38.7%), and No-Tx (34.4%). <br />Results show that No-Tx patients had shorter overall survival (OS) post-PD compared to ATZ-TBP and Other-Tx patients. However, there were no significant differences in OS between ATZ-TBP and Other-Tx patients, indicating delaying subsequent therapies in favor of ATZ-TBP may not negatively impact outcomes. <br />Progression-free survival (PFS) data shows median PFS of 6.5 months for ATZ-TBP, 6.2 months for Other-Tx, and 5.1 months for No-Tx patients. Most ATZ-TBP patients experienced treatment-related adverse events (TRAEs) before PD.<br />The document summarizes the IMfirst study on ATZ-TBP for ES-SCLC. It includes 55 patients, with 10 on ATZ-TBP treatment and 12 on survival follow-up. The median number of ATZ cycles received was 9, 8, and 7 for ATZ-TBP, Other-Tx, and No-Tx patients, respectively. The median duration of treatment was 6.8 months for ATZ-TBP.<br />Adverse events were higher in ATZ-TBP patients before PD compared to after PD. No grade 5 adverse events were reported. The overall response rate and median progression-free survival were similar across the three patient subgroups.<br />The median overall survival since treatment initiation was 14.3 months for ATZ-TBP, 12.6 months for Other-Tx, and 7.2 months for No-Tx patients. Post-PD, the median overall survival was 7.2 months for ATZ-TBP, 6.1 months for Other-Tx, and 1.7 months for No-Tx patients.<br />There were no notable differences in baseline characteristics among the patient subgroups. A similar percentage of ATZ-TBP and Other-Tx patients received subsequent lines of therapy, predominantly chemotherapy/non-anthracyclines. Many ATZ-TBP patients had new lesions at new sites upon progressive disease.<br />In conclusion, delaying subsequent therapies in favor of ATZ-TBP does not appear to negatively impact subsequent lines of therapy in ES-SCLC. The post-PD efficacy and safety data suggest a favorable benefit-risk profile for ATZ-TBP in these patients.

Asset Subtitle

Rosario García-Campelo

Meta Tag

Speaker Rosario García-Campelo

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

atezolizumab

disease progression

untreated extensive-stage small cell lung cancer

ATZ-TBP

patient outcomes

overall survival

progression-free survival

treatment-related adverse events

IMfirst study

subsequent lines of therapy